A Phase II trial to assess the efficacy and safety of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing's disease

Trial Profile

A Phase II trial to assess the efficacy and safety of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing's disease

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Pasireotide (Primary) ; Cabergoline
  • Indications Pituitary ACTH hypersecretion
  • Focus Therapeutic Use
  • Acronyms CAPACITY
  • Sponsors Novartis
  • Most Recent Events

    • 04 Apr 2017 Results assessing safety and efficacy of pasireotide monotherapy or in combination with cabergoline in patients with Cushing's disease, presented at The 99th Annual Meeting of the Endocrine Society.
    • 26 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 26 Nov 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top